C82.6A
BillableCutaneous follicle center lymphoma, in remission
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C82.6A an HCC code?
Yes. C82.6A maps to Breast, Prostate, Colorectal and Other Cancers and Tumors under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C82.6A
For C82.6A to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C82.6A during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C82.6A is the ICD-10-CM diagnosis code for cutaneous follicle center lymphoma, in remission. A type of skin lymphoma affecting follicle center cells that is currently in remission (no active cancer detected). C82.6A sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C82.6A maps to Breast, Prostate, Colorectal and Other Cancers and Tumors (HCC 21) with a community, non-dual, aged base RAF weight of 0.545. Under the older CMS-HCC V24 model, C82.6A maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Only use this code when documentation explicitly states the patient is in remission or complete response. Because C82.6A maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C82.6A sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Only use this code when documentation explicitly states the patient is in remission or complete response
- •This code does not specify anatomical site, so it applies regardless of previous location of disease
Clinical Significance
Cutaneous follicle center lymphoma in remission indicates that this primary skin lymphoma has responded to treatment with no evidence of active disease. Given the excellent prognosis of this lymphoma subtype (>95% 5-year survival), remission is a common and expected outcome. The remission code is used during ongoing surveillance visits and must be documented by the treating physician. Patients may still require periodic skin examinations and imaging to monitor for recurrence.
Documentation Requirements
- ✓Physician documentation explicitly stating remission or complete response
- ✓Dermatologic examination showing resolution of skin lesions
- ✓Most recent imaging confirming no active disease
- ✓Date remission was achieved
- ✓Surveillance schedule and monitoring plan
- ✓Documentation of any maintenance therapy